Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
The possibility that there is an increased risk of melanoma in patients with psoriasis treated with psoralen–UV-A (PUVA) therapy has raised concern on the part of physicians and patients about the long-term safety of this treatment. In response to this concern, the National Psoriasis Foundation sponsored a workshop at which invited participants with expertise in PUVA therapy, psoriasis treatment, melanoma and nonmelanoma skin cancer, and epidemiological and clinical trials were asked to develop a consensus on the following 3 issues: the risk of long-term adverse effects of PUVA therapy with emphasis on nonmelanoma and melanoma skin cancer; the guidelines for physicians and patients for selection and use of PUVA therapy with consideration of the risk-benefit ratio of this treatment compared with the risk-benefit ratios of alternative treatments; and the directions for further evaluation of the long-term effects of PUVA therapy.
Morison WL, Baughman RD, Day RM, et al. Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy. Arch Dermatol. 1998;134(5):595–598. doi:10.1001/archderm.134.5.595
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: